MADRID and WALTHAM, Mass., May 25, 2011 /PRNewswire/ -- Interleukin Genetics, Inc. (OTCQB: ILIU) and Labec Pharma SA today announced that USP Hospitales now offers the innovative Heart Health Genetic Test, developed by Interleukin Genetics, at San Jose, USP Hospitales, the flagship hospital in Madrid, and will soon make it available throughout their hospital network. The test identifies single nucleotide variations in two Interleukin-1 (IL-1) genes that lead to a greater predisposition of cardiovascular events, based on an excessive inflammatory response. Labec will distribute the test through an exclusive license in Spain and Portugal under the CardioHealth™ brand.
"We are pleased that one of the most renowned hospital systems in Spain will make the Heart Health Genetic Test available to its patients," said Lewis H. Bender, chief executive officer, Interleukin Genetics. "Heart disease is largely preventable and the earlier one recognizes their risks, especially their genetic risk, the sooner improved monitoring and prevention can be established."
"Labec Pharma has been working to provide information to leading cardiovascular disease experts in Spain and Portugal about the benefits of the CardioHealth Test," said Javier de Echevarria, chief executive officer at Labec Pharma. "Heart disease is a major problem in Spain and this test has the potential to identify those at greatest risk to allow for improved care. Providing easy access to this vital information will enable patients to take control of their heart health by enacting lifestyle changes to manage their risk factors."
About Heart Disease in SpainInflammation is an important risk factor for heart disease. Some genetic inflammation patterns are responsible for many cardiac events, including heart attacks. In Spain, 56 percent of the population presents an increased risk for developing cardiovascular disease. Cardiovascular disease is the major cause of death in men and women in industrialized countries and is responsible for 31.7 percent of all deaths in Spain (INE data March 2010).
About the CardioHealth Test in SpainThe CardioHealth™ Genetic Test was developed by Interleukin Genetics and reveals whether there is an increased risk of heart attack due to increased Interleukin-1 based inflammation. This simple, quick and painless test evaluates single nucleotide polymorphisms in two genes (Interleukin-1 Alpha and Interleukin-1 Beta) that are key in determining a greater predisposition to excessive levels of inflammation. The results are based on two clinical studies, one in the U.S. and one in Europe, that identified genetic patterns to indicate whether a person has more or less of a probability to suffer a heart attack as a result of this inflammatory activity.
Buccal epithelial cells from a cheek swab are collected for analysis and sent to Interleukin's U.S. headquarters for analysis. After three to four weeks, patients receive a complete report in Spanish outlining their cardiovascular genetic risk. The CardioHealth Genetic Test allows for the detection of an abnormally high risk in people at early age and has utility in the prevention of disease by promoting healthier lifestyles. If the inflammatory genetic factors related to cardiovascular disease are detected in time, one can take appropriate measures to reduce risk.
About Interleukin Genetics Interleukin Genetics, Inc. (OTCQB: ILIU) develops and markets a line of genetic tests under the Inherent Health® brand. The products empower individuals to prevent certain chronic conditions and manage their existing health and wellness through genetic-based insights with actionable guidance. Interleukin Genetics leverages its research, intellectual property and genetic panel development expertise in metabolism and inflammation to facilitate the emerging personalized healthcare market. The Company markets its tests through partnerships with health and wellness companies, healthcare professionals and other distribution channels. In addition to the Heart Health Genetic Test, Interleukin Genetics' products include its proprietary PST® genetic risk panel for periodontal disease and tooth loss susceptibility - sold through dentists - and the Inherent Health Weight Management Genetic Test that identifies the most effective diet and exercise program for an individual based on genetics. Interleukin Genetics is headquartered in Waltham, Mass. and operates an on-site, state-of-the-art DNA testing laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). For more information, please visit www.ilgenetics.com.About USP HospitalesWith a network of 12 hospitals and 20 diagnosis and day surgery clinics, head offices in Madrid and a presence throughout most of Spain, USP Hospitales has consolidated its position as the number one Spanish private hospital group. The cornerstones of its expansion have been quality healthcare, cutting-edge technology and rigorous professional standards. Today, USP Hospitales has 4,000 medical professionals who provide treatment to over two million patients every year. Furthermore, the Group's prime positioning in popular tourism areas and major cities has led it to develop an important programme, USP International Services, for providing healthcare to patients from abroad, assisted by translators specialising in medicine. USP Hospitales' commitment to society and to providing the highest quality of healthcare has built prestige for the company brand, which over the years, has received many important awards in recognition of its work. For further information about USP Hospitales and its products, visit www.usphospitales.com.
About Labec PharmaLabec Pharma is an important Spanish distributor of in-vitro diagnosis tests with a presence in Europe and Latin America. The Firm's focus is to identify and distribute the most state-of-the-art diagnosis technologies. Labec Pharma has numerous agreements with main hospitals and reference laboratories in Spain and Portugal to make these tests available to physicians and patients. Among the different tests distributed by Labec Pharma: CardioHealth is a cardiovascular risk genetic test and HPV OncoTect is a test for early diagnosis of cervical cancer. The main office of Labec Pharma is based in Madrid. For further information about Labec Pharma and its products, visit www.labec.net or contact our press relations office.
Certain statements contained herein are "forward-looking" statements. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, those risks and uncertainties described in the Company's annual report on Form 10-K for the year ended December 31, 2010 and other filings with the Securities and Exchange Commission. The Company disclaims any obligation or intention to update these forward-looking statements.Contacts:Interleukin Media:
Labec Pharma:Jon Siegal / Kirsten Fallon
Javier de EchevarriaSchwartz Communications
Chief Executive Officer781-684-0770
+34 91 515 91 email@example.com
|SOURCE Interleukin Genetics, Inc.|
Copyright©2010 PR Newswire.
All rights reserved